Hank Plain

Hank Plain is a partner with Morgenthaler Ventures. Hank joined Morgenthaler in 2007 after more than 25 years in the life science industry, including co-founding eight medical device startups, serving as CEO of a public medical device company and directing the exits of five companies with a combined value well in excess of $2 billion. He is based in Menlo Park, California and is focused on medical device investments.

Hank is the Vice Chairman of The Foundry, the premier medical device incubator based in Menlo Park, California, where he co-founded Ardian, Cabochon Aesthetics, ForSight Labs, ForSight Vision2, Miramar, Satiety and Transcend. Hank was on the board and a member of the deal committee that helped to successfully negotiate the acquisition of Acclarent by Johnson & Johnson for $785 million in December 2009. He also served as President and CEO of Perclose, Inc. from 1993 to 2000, during which he led the company to $100 million in sales and managed the company’s successful IPO and acquisition in 1999 by Abbott Laboratories for $650 million. He was Chairman of Embolic Protection, where he helped negotiate the acquisition of the company in 2001 by Boston Scientific for $200 million. He also served as a Director at TransVascular until Medtronic acquired the company in 2003 for an undisclosed amount. Previously, Hank worked at Eli Lilly for 12 years in various management positions.